Aktienanalyse zu CorMedix Inc (CRMD)CRMDCorMedix Inc

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CorMedix Inc (CRMD) is currently trading at $7.26, which is significantly below the analyst target price of $15, indicating a potential upside of 106.5%. However, the stock has a low RSI of 32.97, suggesting it is oversold, which could indicate a buying opportunity. The main risk is the forward P/E ratio of 46.51, which suggests that the stock may be overvalued if earnings do not meet expectations in the near term. Therefore, while there is potential for growth, caution is advised due to high valuation metrics and recent performance trends.

1 analysts cover CRMD: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 13.67.